Linde K, Dentchev V, Bondarenko V, Marinova S, Randhagen B, Bratoyeva M, Tsvetanov Y, Romanova Y
Institute of Medical Microbiology and Epidemiology, Karl Marx University, Leipzig, GDR.
Vaccine. 1990 Feb;8(1):25-9. doi: 10.1016/0264-410x(90)90173-j.
Live Shigella flexneri 2a and Shigella sonnei Phase I vaccine candidate strains with two virulence-reducing markers were constructed through stepwise incorporation of weakly attenuating purine auxotrophy with subsequent rifampicin-resistance (RNA polymerase) mutation to yield optimal attenuation. These vaccine candidate strains showed an unaltered plasmid profile; did not cause keratoconjunctivitis in the Sereny test, while being excreted for a short but still marked period and providing partial protection from wild-strain infection; exhibited for guinea-pig conjunctival epithelia, HeLa cells and rat enterocytes a maintained invasiveness with reduced intracellular multiplication with little, if any, reversible cell damage; and produced, just as their ultrasonic lysates, no exudative reaction in the rabbit gut loop test.
通过逐步引入弱减毒嘌呤营养缺陷型并随后进行利福平抗性(RNA 聚合酶)突变以实现最佳减毒,构建了具有两种毒力降低标记的活福氏志贺菌 2a 型和宋内志贺菌 I 期疫苗候选菌株。这些疫苗候选菌株显示出质粒图谱未改变;在 Sereny 试验中不引起角膜结膜炎,同时在短但仍显著的时期内排出,并提供对野生菌株感染的部分保护;对豚鼠结膜上皮、HeLa 细胞和大鼠肠上皮细胞表现出维持的侵袭性,细胞内增殖减少,细胞损伤极少(如果有的话)且几乎没有可逆性;并且,正如它们的超声裂解物一样,在兔肠环试验中不产生渗出反应。